Literature DB >> 26108268

Serum levels of thymus and activation-regulated chemokine can be used in the clinical evaluation of atopic dermatitis.

Chao-Ying Gu1, Lei Gu2, Xia Dou1,3.   

Abstract

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by the predominant infiltration of Th2-type cells in lesional skin. Thymus and activation-regulated chemokine (TARC) is overproduced in AD patients, and its serum levels are significantly higher in individuals with AD than in those with other inflammatory skin diseases.
OBJECTIVES: The purpose of this study was to examine whether serum levels of TARC can assess the severity of AD and be used in the clinical evaluation of AD.
METHODS: A total of 73 AD patients, 11 patients with generalized atopic eczema (AE), and 30 healthy control subjects were enrolled. SCORAD (SCORing of Atopic Dermatitis) indices were calculated according to skin symptom scores. The Th2 chemokines TARC kit was then used to obtain serum TARC values in each group. Finally, statistical analysis was used to identify any correlations between serum TARC level and SCORAD index in AD and AE patients.
RESULTS: Mean serum TARC values were 159.95 in healthy controls, 146.46 in the mild AD group, 202.71 in the moderate AD group, 1216.61 in the severe AD group and 1554.50 in the severe AE group. The serum TARC level was significantly correlated with SCORAD score in AD patients (P < 0.01). However, there was no significant correlation between SCORAD score and TARC in AE patients (P = 0.610).
CONCLUSIONS: The serum TARC level can be used to assess the severity of AD and as a reference index for the fast clinical evaluation of AD.
© 2015 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26108268     DOI: 10.1111/ijd.12830

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  6 in total

1.  Plasma thymus and activation-regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma.

Authors:  Eline A M Zijtregtop; Friederike Meyer-Wentrup; Wai-Chu Wong; Raoull Hoogendijk; Marta Lopez-Yurda; Christian M Zwaan; Auke Beishuizen
Journal:  EJHaem       Date:  2020-07-04

2.  Fermented rice bran prevents atopic dermatitis in DNCB-treated NC/Nga mice.

Authors:  Evelyn Saba; Chun Hee Lee; Da Hye Jeong; Kija Lee; Tae-Hwan Kim; Seong-Soo Roh; Seung-Hyung Kim; Man Hee Rhee
Journal:  J Biomed Res       Date:  2016-05-20

3.  NCM 1921, a Mixture of Several Ingredients, Including Fatty Acids and Choline, Attenuates Atopic Dermatitis in 1-Chloro-2,4-Dinitrobenzene-Treated NC/Nga Mice.

Authors:  Young-Sil Lee; Won-Kyung Yang; Eun-Hee Jo; Seung Ho Shin; Young-Cheol Lee; Min-Cheol Park; Seung-Hyung Kim
Journal:  Nutrients       Date:  2020-01-07       Impact factor: 5.717

4.  Hydrogen water ameliorates the severity of atopic dermatitis-like lesions and decreases interleukin-1β, interleukin-33, and mast cell infiltration in NC/Nga mice.

Authors:  Takuya Kajisa; Takuji Yamaguchi; Ailing Hu; Nobuhiro Suetake; Hiroyuki Kobayashi
Journal:  Saudi Med J       Date:  2017-09       Impact factor: 1.484

5.  Loss of GRHL3 leads to TARC/CCL17-mediated keratinocyte proliferation in the epidermis.

Authors:  Stephen J Goldie; Denny L Cottle; Fiona H Tan; Suraya Roslan; Seema Srivastava; Rhys Brady; Darren D Partridge; Alana Auden; Ian M Smyth; Stephen M Jane; Sebastian Dworkin; Charbel Darido
Journal:  Cell Death Dis       Date:  2018-10-19       Impact factor: 8.469

6.  Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.

Authors:  Jennifer D Hamilton; Sivan Harel; Brian N Swanson; William Brian; Zhen Chen; Megan S Rice; Nikhil Amin; Marius Ardeleanu; Allen Radin; Brad Shumel; Marcella Ruddy; Naimish Patel; Gianluca Pirozzi; Leda Mannent; Neil M H Graham
Journal:  Clin Exp Allergy       Date:  2021-06-26       Impact factor: 5.018

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.